Thrombotic thrombocytopenic purpura as the initial presentation of COVID-19.
作者信息
Beaulieu Marie-Claude, Mettelus Danny Sebastien, Rioux-Massé Benjamin, Mahone Michèle
机构信息
Department of Medicine, Internal Medicine Divison, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada.
Department of Medicine, Hematology Division, Centre hospitalier de I'Université de Montréal, Montréal, QC, Canada.
出版信息
J Thromb Haemost. 2021 Apr;19(4):1132-1134. doi: 10.1111/jth.15231.
Abstract
摘要
相似文献
1
Thrombotic thrombocytopenic purpura as the initial presentation of COVID-19.血栓性血小板减少性紫癜作为新型冠状病毒肺炎的首发表现
J Thromb Haemost. 2021 Apr;19(4):1132-1134. doi: 10.1111/jth.15231.
2
Thrombotic thrombocytopenic purpura (TTP) response following COVID-19 infection: Implications for the ADAMTS-13-von Willebrand factor axis.新型冠状病毒肺炎（COVID-19）感染后的血栓性血小板减少性紫癜（TTP）反应：对ADAMTS-13-血管性血友病因子轴的影响
J Thromb Haemost. 2021 Apr;19(4):1130-1132. doi: 10.1111/jth.15230.
3
Imbalance of von Willebrand factor and ADAMTS13 axis is rather a biomarker of strong inflammation and endothelial damage than a cause of thrombotic process in critically ill COVID-19 patients.在危重症 COVID-19 患者中，血管性血友病因子（von Willebrand factor）与 ADAMTS13 轴的失衡与其说是血栓形成过程的原因，不如说是强烈炎症和内皮损伤的生物标志物。
J Thromb Haemost. 2021 Sep;19(9):2193-2198. doi: 10.1111/jth.15445. Epub 2021 Jul 27.
4
Immune Thrombotic Thrombocytopenic Purpura in a Patient with Suspected COVID-19: Hydroxychloroquine Culprit or Just Happenstance?一名疑似新冠肺炎患者的免疫性血栓性血小板减少性紫癜：羟氯喹是罪魁祸首还是纯属巧合？
Turk J Haematol. 2021 Jun 1;38(2):155-157. doi: 10.4274/tjh.galenos.2021.2021.0057. Epub 2021 Feb 5.
5
von Willebrand Factor Multimer Formation Contributes to Immunothrombosis in Coronavirus Disease 2019.血管性血友病因子多聚体形成有助于 2019 年冠状病毒病的免疫血栓形成。
Crit Care Med. 2021 May 1;49(5):e512-e520. doi: 10.1097/CCM.0000000000004918.
6
COVID-19 as a Potential Trigger for Immune Thrombotic Thrombocytopenic Purpura and Reason for an Unusual Treatment: A Case Report.COVID-19 可能引发免疫性血栓性血小板减少性紫癜及导致采用非常规治疗的原因：一例报告。
Hamostaseologie. 2023 Jun;43(3):215-218. doi: 10.1055/a-1497-1054. Epub 2021 Jul 29.
7
Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine.获得性血栓性血小板减少性紫癜：一种与 BNT162b2 疫苗相关的罕见疾病。
J Thromb Haemost. 2021 Sep;19(9):2314-2317. doi: 10.1111/jth.15420. Epub 2021 Jul 7.
8
Inherited thrombotic thrombocytopenic purpura mimicking immune thrombocytopenic purpura during pregnancy: a case report.孕期表现为免疫性血小板减少性紫癜的遗传性血栓性血小板减少性紫癜：一例报告
J Med Case Rep. 2018 Jan 22;12(1):15. doi: 10.1186/s13256-017-1545-3.
9
Recent advances in thrombotic thrombocytopenic purpura.血栓性血小板减少性紫癜的最新进展
Hematology Am Soc Hematol Educ Program. 2004:407-23. doi: 10.1182/asheducation-2004.1.407.
10
[New marker in thrombotic thrombocytopenic purpura].[血栓性血小板减少性紫癜中的新标志物]
Ugeskr Laeger. 2008 Aug 11;170(33):2446-9.
引用本文的文献
1
Immune thrombotic thrombocytopenic purpura: pathogenesis and novel therapies: a narrative review.免疫性血栓性血小板减少性紫癜：发病机制与新疗法：一篇叙述性综述
Ann Blood. 2023 Sep 30;8. doi: 10.21037/aob-22-29. Epub 2023 Jan 6.
2
Coronavirus disease 2019-associated thrombotic microangiopathy treated with plasma exchange and antihypertensive therapy in a patient with HIV: A case report with literature review.HIV 感染者新冠病毒病相关血栓性微血管病经血浆置换和降压治疗：病例报告并文献复习。
Medicine (Baltimore). 2023 Oct 13;102(41):e35469. doi: 10.1097/MD.0000000000035469.
3
The perfect storm: Thrombotic thrombocytopenic purpura (TTP) associated with COVID-19, a clinical case series and review.完美风暴：与新型冠状病毒肺炎相关的血栓性血小板减少性紫癜（TTP），临床病例系列及综述
EJHaem. 2022 Oct 26;3(4):1358-1364. doi: 10.1002/jha2.577. eCollection 2022 Nov.
4
Hereditary thrombotic thrombocytopenic purpura and COVID-19: Impacts of vaccination and infection in this rare disease.遗传性血栓性血小板减少性紫癜与新型冠状病毒肺炎：疫苗接种和感染对这种罕见疾病的影响
Res Pract Thromb Haemost. 2022 Oct 21;6(7):e12814. doi: 10.1002/rth2.12814. eCollection 2022 Oct.
5
Coronavirus Disease 2019-Associated Thrombotic Microangiopathy: Literature Review.新型冠状病毒病相关血栓性微血管病：文献综述。
Int J Mol Sci. 2022 Sep 25;23(19):11307. doi: 10.3390/ijms231911307.
6
Prognostic value of von Willebrand factor and ADAMTS13 in patients with COVID-19: A systematic review and meta-analysis.COVID-19 患者血管性血友病因子和 ADAMTS13 的预后价值：系统评价和荟萃分析。
Thromb Res. 2022 Oct;218:83-98. doi: 10.1016/j.thromres.2022.08.017. Epub 2022 Aug 18.
7
COVID-19-Associated Thrombotic Thrombocytopenic Purpura: A Case Report and Systematic Review.新型冠状病毒肺炎相关血栓性血小板减少性紫癜：一例报告及系统评价
Hematol Rep. 2022 Aug 2;14(3):253-260. doi: 10.3390/hematolrep14030035.
8
Relapse of immune thrombotic thrombocytopenic purpura (iTTP) possibly triggered by COVID-19 vaccination and/or concurrent COVID-19 infection.COVID-19 疫苗接种和/或同时 COVID-19 感染可能引发免疫性血栓性血小板减少性紫癜（iTTP）复发。
BMJ Case Rep. 2022 Jul 28;15(7):e247524. doi: 10.1136/bcr-2021-247524.
9
Flavorubredoxin, a Candidate Trigger Related to Thrombotic Thrombocytopenic Purpura: Screening of the Complete Genome of a Serovar Typhimurium Isolate From an AIDS Case.风味红血球血绿素，一种与血栓性血小板减少性紫癜相关的候选触发物：从 AIDS 病例中分离的鼠伤寒血清型的完整基因组的筛选。
Front Cell Infect Microbiol. 2022 Jun 10;12:864087. doi: 10.3389/fcimb.2022.864087. eCollection 2022.
10
COVID-19 infection triggering Thrombotic Thrombocytopenic Purpura.新冠病毒感染引发血栓性血小板减少性紫癜。
IDCases. 2021;26:e01256. doi: 10.1016/j.idcr.2021.e01256. Epub 2021 Aug 24.
本文引用的文献
1
The ADAMTS13-von Willebrand factor axis in COVID-19 patients.新冠病毒感染患者中的ADAMTS13-血管性血友病因子轴
J Thromb Haemost. 2021 Feb;19(2):513-521. doi: 10.1111/jth.15191. Epub 2020 Dec 18.
2
Dramatic presentation of acquired thombotic thrombocytopenic purpura associated with COVID-19.与新型冠状病毒肺炎相关的获得性血栓性血小板减少性紫癜的显著表现。
Haematologica. 2020 Oct 1;105(10):e540. doi: 10.3324/haematol.2020.262345.
3
Coagulopathy and Thrombosis as a Result of Severe COVID-19 Infection: A Microvascular Focus.严重 COVID-19 感染导致的凝血功能障碍和血栓形成：微血管焦点。
Thromb Haemost. 2020 Dec;120(12):1668-1679. doi: 10.1055/s-0040-1715841. Epub 2020 Aug 24.
4
Covid-19 associated autoimmune thrombotic thrombocytopenic purpura: Report of a case.新型冠状病毒肺炎相关自身免疫性血栓性血小板减少性紫癜：一例报告
Thromb Res. 2020 Nov;195:136-138. doi: 10.1016/j.thromres.2020.07.005. Epub 2020 Jul 5.
5
COVID-19-associated coagulopathy: An exploration of mechanisms.COVID-19 相关凝血功能障碍：机制探索。
Vasc Med. 2020 Oct;25(5):471-478. doi: 10.1177/1358863X20932640. Epub 2020 Jun 19.
6
The unique characteristics of COVID-19 coagulopathy.COVID-19 凝血功能障碍的独特特征。
Crit Care. 2020 Jun 18;24(1):360. doi: 10.1186/s13054-020-03077-0.
7
Autoimmune thrombotic thrombocytopenic purpura (TTP) associated with COVID-19.与新型冠状病毒肺炎相关的自身免疫性血栓性血小板减少性紫癜
Ann Hematol. 2020 Jul;99(7):1673-1674. doi: 10.1007/s00277-020-04097-0. Epub 2020 May 28.
8
COVID-19, microangiopathy, hemostatic activation, and complement.新型冠状病毒肺炎、微血管病、止血激活与补体
J Clin Invest. 2020 Aug 3;130(8):3950-3953. doi: 10.1172/JCI140183.
9
Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics.血栓性血小板减少性紫癜：发病机制、诊断和潜在的新型治疗方法。
J Thromb Haemost. 2017 Oct;15(10):1889-1900. doi: 10.1111/jth.13764. Epub 2017 Jul 27.
10
Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor.炎症相关的ADAMTS13缺乏促进超大血管性血友病因子的形成。
Haematologica. 2008 Jan;93(1):137-40. doi: 10.3324/haematol.11677.
Zotero 插件